ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 8, 2015

9:00AM-11:00AM
Abstract Number: 330
Calf Muscle Adiposity Is Associated with Impaired Physical Performance in Knee OA
Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors
9:00AM-11:00AM
Abstract Number: 549
Calprotectin (MRP8/MRP14), a Major Leukocyte Protein, Is Highly Associated to Ultrasound Detected Synovitis and Is Responsive to Biologic Treatment
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I
9:00AM-11:00AM
Abstract Number: 604
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I
9:00AM-11:00AM
Abstract Number: 550
Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I
9:00AM-11:00AM
Abstract Number: 630
Can Extraglandular Manifestations Differentiate Primary Sjögren’s Syndrome from Sjögren’s-Systemic Lupus Erythematosus Overlap Syndrome?
Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome
9:00AM-11:00AM
Abstract Number: 662
Can the New Contest Questionnaire Identify Psoriatic Arthritis in a Primary Care Population?
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments
9:00AM-11:00AM
Abstract Number: 365
Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials
Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster
9:00AM-11:00AM
Abstract Number: 262
Canakinumab Therapy in Patients with Familial Mediterranean Fever
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
9:00AM-11:00AM
Abstract Number: 290
Cancer and Necrotizing Immune Mopathy: High Incidence in Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive and Seronegative Patients but Not in Anti-Single Recognition Particle Positive Patients
Muscle Biology, Myositis and Myopathies Poster
9:00AM-11:00AM
Abstract Number: 37
Cardiovascular Disease in Immune-Mediated Inflammatory Diseases: Cross Sectional Analysis of the Influence of Demographic and Traditional Cardiovascular Risk Factors
Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases
9:00AM-11:00AM
Abstract Number: 300
Causes of Creatine Kinase Levels Greater Than 1,000 IU/L in Patients Referred to Rheumatology
Muscle Biology, Myositis and Myopathies Poster
9:00AM-11:00AM
Abstract Number: 10
CD13/Aminopeptidase N Contributes to Angiogenesis and Monocyte Chemotaxis in Rheumatoid Arthritis
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I
9:00AM-11:00AM
Abstract Number: 794
CD163+ Macrophages Display Mixed Polarizations in Discoid Lupus Skin
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 719
Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I
9:00AM-11:00AM
Abstract Number: 818
Cell-Bound Complement Activation Products (CB-CAP) Profiles in Patients with Pre-Systemic Lupus Erythematosus
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I
  • «Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 73
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology